Scribe Therapeutics Inc. (SCTX)
Snapshot
- 1 week
- -23.3%-22.8% vs SPY
- 1 month
- -41.9%-40.9% vs SPY
- Market cap
- $249.4M
- Days to cover
- 3.6
- Short change
- +212.1%
- Consensus
- Buy1 buy · 0 hold · 0 sell
- Price target
- $51.75+235.8% upside
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Scribe Therapeutics Inc. (SCTX). Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
- Benjamin L. OakesCo-Founder, President, CEO & ChairmanUSD 575K
- David L. ParrotCFO & TreasurerUSD 476K
- Svetlana LucasChief Business OfficerUSD 467K
- Jennifer A. DoudnaCo-Founder & Scientific Advisor
- David F. SavageCo-Founder & Scientific Advisor
- Brett T. StaahlCo-Founder & VP of External Innovation
Snapshot
Price & returns1 month -41.9%
- 1 week
- -23.3%-22.8% vs SPY
- 1 month
- -41.9%-40.9% vs SPY
Valuationmarket cap $249.4M
- Market cap
- $249.4M
Short interest & optionsDays to cover 3.6 · Short change +212.1%
- Days to cover
- 3.6
- Short change
- +212.1%
Street & earningsTarget $51.75 (+235.8% upside)1 buy · 0 hold · 0 sell
- Consensus
- Buy1 buy · 0 hold · 0 sell
- Price target
- $51.75+235.8% upside
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Scribe Therapeutics Inc. (SCTX). Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
- Benjamin L. OakesCo-Founder, President, CEO & ChairmanUSD 575K
- David L. ParrotCFO & TreasurerUSD 476K
- Svetlana LucasChief Business OfficerUSD 467K
- Jennifer A. DoudnaCo-Founder & Scientific Advisor
